| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | METHODS TO PREDICT AND PREVENT RESISTANCE TO TAXOID COMPOUNDS | US14865115 | 2015-09-25 | US20160011211A1 | 2016-01-14 | Bruce R. Zetter; Sabarni K. Chatterjee |
| Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. | ||||||
| 182 | TREATMENT-INDUCED DAMAGE TO THE TUMOR MICRO-ENVIRONMENT PROMOTES CANCER THERAPY RESISTANCE THROUGH EXTRACELLULAR PROTEINS | US14418789 | 2013-08-02 | US20150309037A1 | 2015-10-29 | Peter S. Nelson; Yu Sun |
| The present disclosure provides methods for determining the effectiveness of a cancer therapy, as well as methods for increasing the effectiveness of that therapy and determining a prognosis for a patient receiving that therapy. | ||||||
| 183 | Methods to predict and prevent resistance to taxoid compounds | US13404398 | 2012-02-24 | US09151758B2 | 2015-10-06 | Bruce R. Zetter; Sabarni K. Chatterjee |
| Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. | ||||||
| 184 | FUNCTIONAL ASSAY FOR CANCER RECURRENCE AND MALIGNANT POTENTIAL | US14424948 | 2013-08-14 | US20150212072A1 | 2015-07-30 | Sandra S. Mcallister; Zafira Castano |
| Embodiments herein provides an in vitro co-culture system comprising a population of cancer responder cells and a population of non-tumor cells wherein the cancer responder cells can convert to a malignant state and exhibit hallmark malignant phenotype when the cells are placed in a tumor supportive environment. The system is useful for prognosis evaluation of cancer recurrence, malignancy development, cancer drug screening and surveillance for resistance to cancer drug therapy. | ||||||
| 185 | METHODS AND SYSTEMS FOR PREDICTING DRUG-RESPONSE | US14380064 | 2013-02-21 | US20150024409A1 | 2015-01-22 | Nahid Razi |
| Disclosed herein are methods and systems for determining whether a cell is resistant to one or more drugs. Also, disclosed herein are methods and systems for monitoring the treatment of a cancer patient to determine whether the cancerous cells being treated are resistant to the treatment. Further, disclosed herein are methods and systems for predicting the responsiveness of a cell to a drug. Also, disclosed herein are methods and systems to determine the rate of the efficacy of a chemotherapeutic drug on a cancerous, neoplastic or damaged cells | ||||||
| 186 | Using Adaptive Immunity to Detect Drug Resistance | US14365479 | 2012-12-17 | US20140349320A1 | 2014-11-27 | Gregory P. Bisson; Drew Weissman; Harvey Rubin |
| The present invention relates to a method of using adaptive immunity to detect drug resistance in infectious diseases. The invention provides novel antigens associated with drug resistant MTB infection. | ||||||
| 187 | Methods for the identification, assessment, and treatment of patients with cancer therapy | US13600260 | 2012-08-31 | US08889354B2 | 2014-11-18 | Barbara M. Bryant; Andrew I. Damokosh; George J. Mulligan |
| The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting. | ||||||
| 188 | QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS | US14051589 | 2013-10-11 | US20140093890A1 | 2014-04-03 | Walter P. Carney; Peter J. Hamer; Karen Pierce; Sheryl Brown-Shimer |
| The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy. | ||||||
| 189 | ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE | US13983804 | 2012-02-07 | US20140072577A1 | 2014-03-13 | Bret Sellman; Christine Tkaczyk; Lei Hua; Partha Chowdhury; Reena Varkey; Melissa Damschroder; Li Peng; Vaheh Oganesyan; Jamese Johnson Hilliard |
| Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments. | ||||||
| 190 | High Throughput Screening for Antimicrobial Dosing Regimens | US13899876 | 2013-05-22 | US20140011762A1 | 2014-01-09 | Vincent H. Tam; Michael Nikolaou |
| Provided herein are methods and computer-implemented systems for using computer simulations to predict likelihood of a cell population associated with a pathophysiological condition acquiring resistance to a therapeutic agent, to screen for therapeutic agents effective to suppress acquisition of resistance within a cell population and to treat the pathophysiological conditions associated therewith. The computer simulation comprises at least an input/out system and a mathematical model, including operably linked equations, parameter values and constant values, of growth response over a period of time of a cell population in contact with an therapeutic agent. Also provide is a method for determining a best-fit mathematical model of adaptation of a microbial population to a therapeutic agent over time and using the model to simulate microbial population behavior to a therapeutic agent. | ||||||
| 191 | POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | US13711281 | 2012-12-11 | US20130309665A1 | 2013-11-21 | Ulrich Brinkmann; Sven Hoffmeyer; Esther Mornhinweg |
| The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide. Furthermore, provided herein are uses of the polynucleotides, genes, vectors, polypeptides or antibodies herein. | ||||||
| 192 | CD20 negatively converted B-cell malignant lymphoma cell line and utilization thereof | US12311281 | 2007-09-21 | US08496927B2 | 2013-07-30 | Tomoki Naoe; Akihiro Tomita; Junji Hiraga |
| It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient. | ||||||
| 193 | METHODS AND COMPOSITIONS FOR CELL PERMEABLE STAT3 INHIBITOR | US13806639 | 2011-06-22 | US20130177979A1 | 2013-07-11 | James Turkson |
| Disclosed herein are compositions for inhibition of Stat, particularly Stat3. Disclosed herein are compositions comprising cell permeable Stat3 inhibitors. Compositions may comprise peptides, polypeptides, antibodies, nucleic acids, vectors, and host cells for making, using, assaying, and evaluating Stat3 inhibitors. Disclosed herein are methods for making and using the disclosed compositions. | ||||||
| 194 | MASS SPECTROMETRIC MEASUREMENT OF B-LACTAMASE RESISTANCES | US13582372 | 2011-06-10 | US20130095511A1 | 2013-04-18 | Markus Kostrzewa; Karsten Michelmann; Katrin Sparbier |
| The invention relates to the determination of resistances of microorganisms which produce β-lactamases, in particular “extended spectrum β-lactamases” (ESBL). The invention provides a method whereby the microbial resistance can be measured very simply and quickly by means of the catalytic effect of the microbially produced β-lactamases on β-lactam antibiotics, which consists in a hydrolytic cleavage of the β-lactam ring. The method determines the resistance of the bacteria a few hours after a suitable substrate, either a β-lactam antibiotic or a customized β-lactam derivative, has been added to a suspension of the microbes, by direct mass spectrometric measurement of the substrate breakdown caused by the β-lactamases. | ||||||
| 195 | Predictive and therapeutic markers in ovarian cancer | US11814798 | 2006-01-19 | US08404829B2 | 2013-03-26 | Joe W. Gray; Yinghui Guan; Wen-Lin Kuo; Jane Fridlyand; Gordon B. Mills |
| Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described. | ||||||
| 196 | Method of reversing carboplatin resistance by inhibition of HGFIN | US13085612 | 2011-04-13 | US08383806B2 | 2013-02-26 | Pranela Rameshwar |
| The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells. | ||||||
| 197 | DIAGNOSTIC MARKER FOR EFFECT OF ANTICANCER AGENT | US13635911 | 2011-03-18 | US20130029357A1 | 2013-01-31 | Nobuyuki Ise; Daisuke Nambara; Kazuya Omi |
| The present invention enables to realize a convenient determination of a therapeutic effect of an anticancer agent on a cancer. Specifically, the present invention provides a diagnostic marker for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET; a diagnostic reagent for an effect of an anticancer agent on a cancer, comprising a substance having an affinity for a fragment of an extracellular domain of c-MET and the fragment of the extracellular domain of c-MET; and a method of testing an effect of an anticancer agent on a cancer, comprising (a) measuring a concentration of a fragment of an extracellular domain of c-MET in a biological sample from a subject, and (b) comparing the measured concentration of the fragment of the extracellular domain of c-MET with an indicator which presents a relationship between a concentration of the fragment of the extracellular domain of c-MET and the effect of the anticancer agent on the cancer. | ||||||
| 198 | METHODS TO PREDICT AND PREVENT RESISTANCE TO TAXOID COMPOUNDS | US13404398 | 2012-02-24 | US20130028885A1 | 2013-01-31 | Bruce R. Zetter; Sabarni K. Chatterjee |
| Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. | ||||||
| 199 | Methods for the identification, assessment, and treatment of patients with cancer therapy | US11449195 | 2006-06-08 | US08278038B2 | 2012-10-02 | Barbara M. Bryant; Andrew I. Damokosh; George Mulligan |
| The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting. | ||||||
| 200 | Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists | US13356739 | 2012-01-24 | US20120122724A1 | 2012-05-17 | Tong Zhou; Robert P. Kimberly |
| Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | ||||||
QQ群二维码
意见反馈
意见反馈